Suggested remit - To appraise the clinical and cost effectiveness of rivaroxaban within its marketing authorisation for treating heart failure in people with coronary heart disease
- Status:
- Awaiting development
- Decision:
- None selected
- Process:
- TA
- ID number:
- 1462
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 27 September 2018 - 25 October 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 09 October 2018 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual